TTR and amyloidosis: Phase I-III study for the treatment of hereditary transthyretin-mediated amyloidosis. Characterized by peripheral sensorimotor and autonomic neuropathy. RNA interference that reduces production of both wild-type and mutant transthyretin protein. Phase III APOLLO study showed significant improvement in polyneuropathy.